The 2026 Ebola pandemic prediction market asks whether the Ebola virus will reach pandemic status during the calendar year 2026. In epidemiological terms, a pandemic is defined as a disease outbreak that has spread across multiple countries or continents, typically affecting a large number of people. Ebola, a severe and often fatal viral hemorrhagic fever, has historically caused localized outbreaks in Central and West Africa, with the largest epidemic occurring in West Africa from 2014 to 2016, which resulted in over 28,000 cases and 11,000 deaths. The possibility of a pandemic-level Ebola event in 2026 hinges on factors such as the virus's mutation rate, the effectiveness of outbreak containment measures, global travel patterns, and the availability of vaccines and treatments. Recent developments have improved the tools available to combat Ebola. The rVSV-ZEBOV vaccine (Ervebo), developed by Merck, has been used in ring vaccination campaigns in Democratic Republic of Congo and Guinea, showing high efficacy. Additionally, two monoclonal antibody treatments, REGN-EB3 and mAb114, have been approved for Ebola virus disease, significantly reducing mortality when administered early. However, challenges remain: vaccine coverage is not universal in endemic regions, and the virus can persist in survivors, leading to new flare-ups. The World Health Organization (WHO) has a list of priority diseases for research and development, and Ebola remains a high-priority pathogen due to its potential to cause severe outbreaks. The interest in this prediction market likely stems from the broader concern about emerging infectious diseases, especially after the COVID-19 pandemic demonstrated the global impact of a novel virus. While Ebola is less transmissible than respiratory viruses like SARS-CoV-2, a mutation that increases its transmissibility could change that picture. Scientists monitor the virus's evolution, but as of now, no such mutation has been observed. The market also reflects a general public interest in pandemic preparedness and the role of international health regulations in preventing global spread. For those following the market, the resolution depends on an official declaration of a pandemic by the WHO or a consensus among health authorities that the outbreak meets the criteria. Historically, the WHO has been cautious in using the term 'pandemic' for Ebola, reserving it for the 2014-2016 outbreak. In 2026, the likelihood of a pandemic-level Ebola event is considered low by most experts, but the market allows traders to express their views on the probability based on current data and trends.

Historical Context

Ebola was first identified in 1976 in simultaneous outbreaks in Sudan and Zaire (now DRC). The virus is named after the Ebola River in DRC. Since then, there have been over 30 outbreaks, mostly in Central Africa, with case fatality rates ranging from 25% to 90%. The largest outbreak occurred in West Africa from 2014 to 2016, beginning in Guinea and spreading to Sierra Leone and Liberia. That epidemic was declared a PHEIC by the WHO, and it highlighted the vulnerabilities of health systems in low-income countries. The outbreak resulted in over 28,000 cases and 11,000 deaths, with a case fatality rate of about 40%. It also led to significant economic losses, estimated at $2.2 billion in GDP across the three countries. The aftermath of the West Africa epidemic spurred investments in vaccine and therapeutic development. The rVSV-ZEBOV vaccine was tested in a clinical trial during the 2014-2016 outbreak, but it was not until 2019 that it was licensed. Since then, it has been used in ring vaccination campaigns in DRC and Guinea, proving effective in curtailing outbreaks. The DRC has experienced several outbreaks since 2018, including a major one in North Kivu and Ituri that lasted from 2018 to 2020, with over 3,400 cases. That outbreak was complicated by armed conflict and community mistrust, leading to a high case fatality rate of 66%. More recently, an outbreak in Uganda in 2022 caused by the Sudan ebolavirus species was contained within months, thanks to rapid response and the use of experimental vaccines. The WHO has also prequalified a second vaccine, the Johnson & Johnson two-dose regimen, which is used in non-ring settings. These tools have changed the dynamics of outbreak control, but the virus remains a threat due to zoonotic spillover from wildlife, especially fruit bats, and the persistence of the virus in survivors, which can lead to new chains of transmission.